alphaRep-HR2 entry inhibitors and a non-antigenic test for the treatment and diagnosis of COVID-19

Forschungsstelle

INNOSUISSE

Projektnummer

54121.1 IP-LS

Projekttitel

alphaRep-HR2 entry inhibitors and a non-antigenic test for the treatment and diagnosis of COVID-19

Projekttitel Englisch

alphaRep-HR2 entry inhibitors and a non-antigenic test for the treatment and diagnosis of COVID-19

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-	-

Kategorie	Text
Kurzbeschreibung (Deutsch)	alphaRep-HR2 entry inhibitors and a non-antigenic test for the treatment and diagnosis of COVID-19
Kurzbeschreibung (Englisch)	alphaRep-HR2 entry inhibitors and a non-antigenic test for the treatment and diagnosis of COVID-19
Abstract (Deutsch)	The SARS-CoV2 pandemic is a major health, economic and societal issue worldwide. Despite the advent of vaccines, novel therapeutic and diagnostic options are needed. Here, we wish to use S artificial nanoligands to develop novel potent entry inhibitors and a non-antigenic test for massive screening.